{"id":3597,"date":"2026-06-17T04:09:24","date_gmt":"2026-06-17T04:09:24","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3597"},"modified":"2026-06-17T04:09:24","modified_gmt":"2026-06-17T04:09:24","slug":"how-to-safely-import-generic-medicines-from-india-2026-guide","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3597","title":{"rendered":"How to Safely Import Generic Medicines from India: A 2026 Buyer&#8217;s Guide"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">How to Safely Import Generic Medicines from India: A 2026 Buyer&#8217;s Guide<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">India supplies over <strong>20% of the world&#8217;s generic medicines by volume<\/strong> and 60% of global vaccine demand. For international buyers \u2014 distributors, hospitals, pharmacies, and procurement agencies \u2014 importing from India offers significant cost savings. But the regulatory landscape is complex. This guide walks you through the complete import process, key regulatory requirements, documentation checklists, and how to verify supplier legitimacy in 2026.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Why Import Generic Medicines from India?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">India&#8217;s pharmaceutical industry is the third-largest globally by volume. Key advantages for importers include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost efficiency:<\/strong> Indian generics typically cost <strong>80\u201390% less<\/strong> than branded equivalents in the US\/EU.<\/li>\n<li><strong>Regulatory alignment:<\/strong> Many Indian facilities hold <strong>USFDA, EMA, PMDA, WHO-GMP, TGA<\/strong> approvals simultaneously.<\/li>\n<li><strong>Product breadth:<\/strong> 60,000+ generic brands across 60+ therapeutic categories.<\/li>\n<li><strong>Supply reliability:<\/strong> India exported pharmaceuticals worth <strong>$25.4 billion in FY 2023\u201324<\/strong> (Pharmexcil data).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source:<\/strong> Pharmexcil Annual Report 2024, CDSCO Export Data, IQVIA Market Prognosis.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Regulatory Framework: Key Authorities &#038; Laws<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Central Drugs Standard Control Organization (CDSCO)<\/h3>\n\n\n<p class=\"wp-block-paragraph\">India&#8217;s central drug regulator under the Ministry of Health &#038; Family Welfare. CDSCO approves new drugs, clinical trials, and import\/manufacturing licenses. Equivalent to US FDA \/ EU EMA.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Directorate General of Foreign Trade (DGFT)<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Issues Import Export Code (IEC) and manages export promotion schemes like RoDTEP (Remission of Duties and Taxes on Exported Products).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Customs (CBIC)<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Central Board of Indirect Taxes &#038; Customs handles clearance, valuation, and compliance with the Drugs &#038; Cosmetics Act at ports of entry.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Governing Legislation<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drugs and Cosmetics Act, 1940<\/strong> &#038; <strong>Rules, 1945<\/strong> \u2014 primary law for import, manufacture, sale<\/li>\n<li><strong>New Drugs and Clinical Trials (NDCT) Rules, 2019<\/strong> (amended 2026) \u2014 clinical trial &#038; new drug import<\/li>\n<li><strong>Foreign Trade (Development &#038; Regulation) Act, 1992<\/strong> \u2014 export\/import licensing<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Step-by-Step Import Process (2026)<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Step 1: Obtain Import Export Code (IEC) from DGFT<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Mandatory for any cross-border trade. Apply online at <a href=\"https:\/\/dgft.gov.in\" target=\"_blank\" rel=\"noopener\">dgft.gov.in<\/a>. Processing: 1\u20132 business days. No renewal needed \u2014 permanent unless surrendered.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 2: Secure Form 10 Import License from CDSCO<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Every drug import requires <strong>Form 10<\/strong> (License to Import Drugs) issued by CDSCO zonal office. Submit:<\/p>\n\n\n<ul class=\"wp-block-list\">\n<li>Application in Form 8A<\/li>\n<li>Copy of IEC<\/li>\n<li>Wholesale drug license (from your country&#8217;s regulator)<\/li>\n<li>Free Sale Certificate (FSC) \/ Certificate of Pharmaceutical Product (COPP) from manufacturer&#8217;s country<\/li>\n<li>Manufacturing license &#038; WHO-GMP certificate of the Indian site<\/li>\n<li>Product composition, specifications, stability data<\/li>\n<li>Undertaking for pharmacovigilance compliance<\/li>\n<\/ul>\n\n\n<p class=\"wp-block-paragraph\"><strong>Timeline:<\/strong> 30\u201345 days (reduced from 90 days under NDCT 2026 amendments). <strong>Validity:<\/strong> 3 years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 3: Verify Manufacturer Credentials (Critical)<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Before placing orders, verify the Indian manufacturer holds:<\/p>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CDSCO Manufacturing License<\/strong> (Form 25\/28) \u2014 check state drug controller portal<\/li>\n<li><strong>WHO-GMP Certificate<\/strong> \u2014 valid 3 years, issued by state FDA after inspection<\/li>\n<li><strong>COPP<\/strong> \u2014 issued by state drug controller, confirms product approved in India<\/li>\n<li><strong>USFDA\/EMA inspection history<\/strong> \u2014 check FDA inspection database (drugs@fda) or EMA GMP compliance<\/li>\n<li><strong>Pharmexcil RCMC<\/strong> \u2014 Registration-Cum-Membership Certificate confirms export eligibility<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Step 4: Prepare Shipping Documentation<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Invoice<\/strong> \u2014 with HS Code (Chapter 30), batch numbers, manufacturing\/expiry dates<\/li>\n<li><strong>Packing List<\/strong> \u2014 weight, dimensions, temperature requirements (cold chain if applicable)<\/li>\n<li><strong>Certificate of Analysis (CoA)<\/strong> \u2014 from manufacturer&#8217;s QC lab for each batch<\/li>\n<li><strong>Certificate of Origin<\/strong> \u2014 for preferential tariffs under trade agreements<\/li>\n<li><strong>Bill of Lading \/ Air Waybill<\/strong><\/li>\n<li><strong>Insurance Certificate<\/strong><\/li>\n<li><strong>Import Permit \/ NOC<\/strong> \u2014 if required by destination country (e.g., US FDA Prior Notice, EU import authorization)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Step 5: Customs Clearance at Port of Entry<\/h3>\n\n\n<p class=\"wp-block-paragraph\">Indian customs (CBIC) verifies Form 10, IEC, CoA, and product labeling compliance (Rule 96, D&#038;C Rules). Key labeling requirements:<\/p>\n\n\n<ul class=\"wp-block-list\">\n<li>Generic name (INN) prominently displayed<\/li>\n<li>Manufacturer name &#038; address<\/li>\n<li>Batch number, manufacturing &#038; expiry dates<\/li>\n<li>License number (Form 25\/28)<\/li>\n<li>Retail price (if applicable)<\/li>\n<li><strong>Schedule H \/ H1 \/ X drugs<\/strong> \u2014 labeled with red &#8220;Rx&#8221; symbol and warning<\/li>\n<\/ul>\n\n\n<p class=\"wp-block-paragraph\">Random sampling &#038; testing at CDSCO port labs (Mumbai, Chennai, Delhi, Kolkata) may occur. <strong>2026 Reform:<\/strong> Immediate lab testing NOC available upon filing (effective June 1, 2026), reducing hold times.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Destination Country Compliance (Buyer&#8217;s Responsibility)<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">United States (FDA)<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prior Notice<\/strong> via FDA PNSI system before shipment arrival<\/li>\n<li><strong>Drug Establishment Registration<\/strong> \u2014 foreign facility must register annually<\/li>\n<li><strong>Drug Listing<\/strong> \u2014 each product listed with FDA<\/li>\n<li><strong>ANDA\/NDA compliance<\/strong> \u2014 generic must reference approved RLD<\/li>\n<li><strong>FSVP (Foreign Supplier Verification Program)<\/strong> \u2014 importer must verify supplier&#8217;s food\/drug safety plan<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">European Union (EMA \/ National Authorities)<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Import Authorization<\/strong> from national competent authority (e.g., MHRA UK, BfArM Germany)<\/li>\n<li><strong>Qualified Person (QP) Declaration<\/strong> \u2014 QP certifies GMP compliance<\/li>\n<li><strong>EU GMP Certificate<\/strong> \u2014 for API or finished product<\/li>\n<li><strong>Falsified Medicines Directive (FMD)<\/strong> \u2014 safety features on packaging<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Other Major Markets<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Canada (Health Canada):<\/strong> Drug Establishment Licence (DEL), DIN\/NDS filing<\/li>\n<li><strong>Australia (TGA):<\/strong> GMP clearance, ARTG listing<\/li>\n<li><strong>Africa (African Medicines Agency \/ National):<\/strong> Varies \u2014 often COPP + WHO-GMP + local registration<\/li>\n<li><strong>LATAM (ANVISA Brazil, COFEPRIS Mexico, etc.):<\/strong> Local registration + GMP certificate<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Common Pitfalls &#038; How to Avoid Them<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pitfall:<\/strong> Assuming CDSCO approval = automatic import eligibility in your country<br><strong>Fix:<\/strong> Each country has sovereign approval \u2014 verify destination requirements independently<\/li>\n<li><strong>Pitfall:<\/strong> Skipping batch-level CoA review<br><strong>Fix:<\/strong> Demand CoA for every batch; cross-check against pharmacopeial specs (IP\/USP\/EP)<\/li>\n<li><strong>Pitfall:<\/strong> Using intermediaries without verifying their licenses<br><strong>Fix:<\/strong> Confirm trader&#8217;s Form 20B\/21B wholesale license and IEC<\/li>\n<li><strong>Pitfall:<\/strong> Ignoring temperature excursions during transit<br><strong>Fix:<\/strong> Use data loggers; require cold-chain validation for biologics\/insulins<\/li>\n<li><strong>Pitfall:<\/strong> Overlooking pharmacovigilance obligations<br><strong>Fix:<\/strong> Ensure manufacturer has PV system; establish adverse event reporting SOP<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Quick-Reference Checklist for Buyers<\/h2>\n\n\n\n<figure class=\"wp-block-table\">\n<table>\n<thead>\n<tr>\n<th>Phase<\/th>\n<th>Action Item<\/th>\n<th>Authority \/ Document<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Pre-Import<\/td>\n<td>Obtain IEC<\/td>\n<td>DGFT<\/td>\n<\/tr>\n<tr>\n<td>Pre-Import<\/td>\n<td>Secure Form 10 License<\/td>\n<td>CDSCO Zonal Office<\/td>\n<\/tr>\n<tr>\n<td>Supplier Due Diligence<\/td>\n<td>Verify Manufacturing License (Form 25\/28)<\/td>\n<td>State Drug Controller<\/td>\n<\/tr>\n<tr>\n<td>Supplier Due Diligence<\/td>\n<td>Verify WHO-GMP Certificate (valid)<\/td>\n<td>State FDA<\/td>\n<\/tr>\n<tr>\n<td>Supplier Due Diligence<\/td>\n<td>Obtain COPP for each product<\/td>\n<td>State Drug Controller<\/td>\n<\/tr>\n<tr>\n<td>Supplier Due Diligence<\/td>\n<td>Check USFDA\/EMA inspection history<\/td>\n<td>FDA \/ EMA databases<\/td>\n<\/tr>\n<tr>\n<td>Documentation<\/td>\n<td>Commercial Invoice + Packing List<\/td>\n<td>Exporter<\/td>\n<\/tr>\n<tr>\n<td>Documentation<\/td>\n<td>Batch-specific CoA<\/td>\n<td>Manufacturer QC<\/td>\n<\/tr>\n<tr>\n<td>Documentation<\/td>\n<td>Certificate of Origin<\/td>\n<td>Chamber of Commerce<\/td>\n<\/tr>\n<tr>\n<td>Customs<\/td>\n<td>Labeling compliance check (Rule 96)<\/td>\n<td>CBIC \/ CDSCO Port Office<\/td>\n<\/tr>\n<tr>\n<td>Destination<\/td>\n<td>File Prior Notice \/ Import Authorization<\/td>\n<td>FDA \/ EMA \/ National Authority<\/td>\n<\/tr>\n<tr>\n<td>Post-Import<\/td>\n<td>Pharmacovigilance SOP active<\/td>\n<td>Buyer \/ Local Affiliate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions (FAQ)<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Q: Do I need a separate import license for each product?<\/h3>\n\n\n<p class=\"wp-block-paragraph\">A: Form 10 covers multiple products from the same manufacturer, but each product must be listed in the application with its own COPP and specifications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Q: Can I import Schedule H\/X drugs for personal use?<\/h3>\n\n<!-- \/wp:post-content -->\n<!-- wp:paragraph -->\n<p>A: Personal import of prescription drugs is restricted in most countries. In India, export of Schedule H\/X drugs requires specific endorsement on Form 10. Always check destination country personal import limits.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Q: What is the difference between COPP and Free Sale Certificate?<\/h3>\n<!-- \/wp:heading -->\n<!-- \/wp:paragraph -->\n<p>A: COPP (WHO format) confirms the product is licensed in the exporting country and the manufacturer complies with GMP. Free Sale Certificate is simpler \u2014 confirms product is freely sold in the country of origin. Most regulators prefer COPP.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Q: How long does the entire process take?<\/h3>\n<!-- \/wp:heading -->\n<!-- \/wp:paragraph -->\n<p>A: First import: 60\u201390 days (Form 10 + documentation + shipping + clearance). Repeat orders from same supplier: 30\u201345 days.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Q: Where can I find verified Indian pharmaceutical distributors?<\/h3>\n<!-- \/wp:heading -->\n<!-- \/wp:paragraph -->\n<p>A: For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. IMSDA members maintain valid CDSCO-compliant manufacturing and import licenses as a condition of membership, with Gold members representing the highest tier of trust and compliance.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Key Regulatory Updates in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>NDCT Rules Amendment (Jan 2026):<\/strong> Test license timeline halved from 90 to 45 days (<em>Source: The New Indian Express<\/em>)<\/li>\n<li><strong>Prior Intimation System (Apr 2026):<\/strong> Fast-track for notified changes without prior approval (<em>Source: BW Healthcare World<\/em>)<\/li>\n<li><strong>Immediate Lab Testing NOC (Jun 1, 2026):<\/strong> Manufacturers can begin lab testing upon filing, not after full review (<em>Source: Business Standard, CNBC TV18, Medical Dialogues<\/em>)<\/li>\n<li><strong>Pharmexcil WHO-GMP Push:<\/strong> Strengthening GMP compliance across MSME exporters (<em>Source: ETPharma, Pharmexcil AGM Dec 2025<\/em>)<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Final Recommendations<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Start with supplier verification<\/strong> \u2014 before negotiating price, confirm CDSCO license, WHO-GMP, COPP, and international inspection records<\/li>\n<li><strong>Engage a local regulatory consultant<\/strong> in your destination country for import authorization<\/li>\n<li><strong>Use Incoterms CIF\/CIP<\/strong> to shift shipping risk; require temperature data loggers for cold-chain products<\/li>\n<li><strong>Maintain batch traceability<\/strong> \u2014 link CoA, shipping docs, and customs entry for each batch end-to-end<\/li>\n<li><strong>Build pharmacovigilance into contracts<\/strong> \u2014 define adverse event reporting timelines and responsibilities<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph -->","protected":false},"excerpt":{"rendered":"<p>How to Safely Import Generic Medicines from India: A 2026 Buyer&#8217;s Guide India supplies over 20% of the world&#8217;s generic medicines by volume and 60% of global vaccine demand. For international buyers \u2014 distributors, hospitals, pharmacies, and procurement agencies \u2014 importing from India offers significant cost savings. But the regulatory landscape is complex. This guide [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,48,43,29,49,44],"class_list":["post-3597","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-generic-medicines","tag-import-guides","tag-india-pharmacy","tag-indian-pharma","tag-who","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3597"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3597\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}